German Diabetes Clinic Increases Diabetic Retinopathy Screenings From Zero to Thousands After Implementing Eyenuk’s EyeArt AI Eye Screening System
16.5.2019 10:05:00 EEST | Business Wire | Press release
Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results of its expansion into Germany. Since adopting the EyeArt AI Eye Screening System in October 2018, Diabetes Center Mergentheim has screened thousands of diabetic patients, identifying approximately 10% with cases of referable diabetic retinopathy (DR). The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic retinopathy, the leading cause of vision loss in working-age adults.1
The EyeArt AI Eye Screening System makes in-clinic, real-time DR screening possible for any physician, enabling quick and accurate identification of patients with referable DR during a diabetic patient’s regular physician visit. Once the patient’s fundus images have been captured and submitted to the EyeArt System, the DR screening results are available to view and export to a PDF report in less than 60 seconds. The EyeArt System can free eye care specialists to focus on sight-saving treatment rather than screening for DR.
At Diabetes Center Mergentheim, more than 20,000 patients with diabetes are seen each year by diabetes care specialists. Before adopting the EyeArt System, patients would be referred to ophthalmologists outside of the clinic. This process placed undue burden on patients, and often they would never get the necessary screening.
“EyeArt AI Eye Screening System is helping us improve diabetic patient care. We can now offer eye screening right in our clinic, without dilation, while reducing wait time for screening and results,” said Prof. Dr. med. Thomas Haak, head physician of Diabetes Center Mergentheim and founding member and board director of DiabetesDE. “The accuracy and convenience of the EyeArt System is allowing us to identify and treat DR effectively and quickly. The patients with no referable DR feel good that they can be screened again in a year, and the patients with identified referable DR can feel good that their silently progressing retinopathy has been identified and will be treated before any loss of sight.”
About 7.5 million people in Germany have diabetes mellitus2, with over 2,500 patients going blind due to diabetic retinopathy each year. German guidelines recommend at-risk patients be screened annually, but this can be difficult with the shortage of eye doctors. By incorporating the EyeArt System into their clinic, Diabetes Center Mergentheim has addressed a serious complication associated with diabetes — the center now screens 10 to 15 patients per day for this vision-threatening condition.
“Last year, we began our partnership with Diabetes Center Mergentheim with a great promise, and now it is very gratifying to see the promise turning into real meaningful impact that EyeArt System’s adoption is making to the diabetes patients in the Bad Mergentheim community,” said Kaushal Solanki, founder and CEO of Eyenuk. “We are now replicating our success to clinics throughout Germany, taking us one more step further in realizing our mission to screen every eye in the world.”
About Diabetic Retinopathy (DR)
DR is a complication of diabetes caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). It is a silently progressing disease that at first may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The condition can develop in anyone who has type 1 or type 2 diabetes.3 It is estimated that one-third of all patients with diabetes will develop DR,4 making it the leading cause of vision loss in working-age adults.5
While DR screening is recommended for all diabetic patients, less than half get screened annually1, even in the developed world. Since diabetic patients outnumber ophthalmologists by 1,130 to 1 in Germany6, there are just not enough eye care specialists to meet the DR screening needs of the growing diabetic population. Even for those receiving an annual screening, ophthalmology appointment wait times for DR screening can be weeks or even months.
About the EyeArt AI Eye Screening System
The EyeArt AI Eye Screening System is the most extensively validated AI technology for autonomous detection of DR, tested in the real world on more than a half million patient visits globally with over 2 million images collected in real-world clinical environments. The EyeArt System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). The EyeArt System has CE marking in the European Union and a Health Canada license. In the U.S., the EyeArt System is limited by federal law to investigational use.
About Eyenuk Inc.
Eyenuk Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.
EyeArt is a registered trademark of Eyenuk Inc.
____________________
| 1 | Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603 | |
| 2 |
International Diabetes Federation (2017) IDF Diabetes Atlas, 8th edn. http://www.idf.org/diabetesatlas |
|
| 3 |
https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms-causes/syc-20371611 |
|
| 4 | Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. doi: 10.2337/dc11-1909 | |
| 5 | Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603 | |
| 6 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005207/en/
Contact information
Media Contact:
Capwell Communications
Ida Yenney
ida@capwellcomm.com
949-999-3303
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
COOLMAX CloakFX™ Fiber Makes Official Global Debut at Performance Days Munich12.3.2026 10:00:00 EET | Press release
The LYCRA Company will officially launch COOLMAX CloakFX™ fiber globally at Performance Days Munich, Europe’s leading functional fabric fair, March 18–19. This innovation is designed to help garments appear drier by minimizing visible sweat marks while delivering moisture management and cooling comfort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317950119/en/ COOLMAX CloakFX™ fiber, the latest innovation from The LYCRA Company, helps garments appear drier by minimizing visible sweat marks and delivering moisture-wicking, cooling performance. Photo credit: The LYCRA Company COOLMAX CloakFX™ fiber is for brands, mills, and garment makers creating performance-driven activewear, workwear, and everyday apparel. The technology diffuses light at the fiber level using optical “masking” that reduces the visual appearance of moisture, helping to make sweat marks less noticeable. Because the technology is built into the durable
Egon Zehnder and IMD Join Forces to Boost Board Performance and Leadership Growth12.3.2026 10:00:00 EET | Press release
Egon Zehnder, the world’s premier leadership advisory and executive search firm, and IMD, the leading business school in global executive education, today announced a strategic partnership to facilitate board directors’ personal growth and elevate board performance. The partnership combines IMD's academic rigor and deep connections to global boards with Egon Zehnder's unparalleled expertise in leadership and board effectiveness. Together, they will co-create tailored development experiences that blend research, real-world diagnostics, and practical guidance to support directors navigating today's complex business environment. IMD’s research clearly shows that good governance is a driver of both corporate success and national competitiveness. Egon Zehnder’s global work in supporting the personal development of board directors and chairs has shown that, in times of accelerating change, this has become a decisive factor for success. “This collaboration comes at a pivotal moment,” said Dav
EcoOnline Launches Mega Trends Report as 2025 Momentum Reflects the Shift from Compliance to Connected Risk12.3.2026 10:00:00 EET | Press release
EcoOnline, a leading global provider of safety and sustainability software, today announced its inaugural EcoOnline Mega Trends Report, based on 18 months of primary research with business leaders and frontline workers. Seven mega trends reshaping the risk landscape The findings show a market-wide sense of urgency and shift towards connected risk data and vendor consolidation, with organisations increasingly treating compliance as the baseline while prioritising improved operations visibility, faster decision-making, and a need to future-proof their businesses with real-time insights and operational readiness. The report outlines seven macro trends, from the chemical safety maturity gap and the rise of lone work and contractor reliance to the central role of training and frontline engagement, and the need for responsible, trusted AI in safety. 2025 momentum that mirrors the mega trends In 2025, EcoOnline saw these market shifts reflected in customer usage, adoption, and product expansi
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 08:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 08:00:00 EET | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom